Physician profile
Michael C Mobley
NPI 1386626646
$3,226.34
in general payments reported to CMS, 2019-2025
28 companies · $99.82 in 2025
The $99.82 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $598 · 2021: $1,113 · 2022: $628 · 2025: $99.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $99.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $99.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $522.80 | 2019-2022 | |
| Allergan, INC. | $483.95 | 2019-2020 | |
| Abbvie INC. | $359.34 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $340.05 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.77 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $279.97 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $201.43 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $166.30 | 2019-2022 | |
| Alkermes, INC. | $122.02 | 2021-2022 | |
| Biogen, INC. | $99.82 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $91.13 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $78.85 | 2019 | |
| Eisai INC. | $47.06 | 2020 | |
| Neurocrine Biosciences, INC. | $36.62 | 2020-2021 | |
| Alfasigma USA, INC. | $33.91 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $19.86 | 2020 | |
| Lundbeck LLC | $19.44 | 2022 | |
| Adlon Therapeutics L.P. | $17.10 | 2020 | |
| Acadia Pharmaceuticals INC | $15.92 | 2021 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.